within Pharmacolibrary.Drugs.ATC.J;

model J05AX27
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.94,
    Cl             = 14.0 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 1600 / 1000000,
    adminCount     = 1,
    Vd             = 0.0159,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.00975,
    Tlag           = 10.200000000000001
  );

  annotation(Documentation(
    info ="<html><body><p>Favipiravir is an antiviral drug developed for the treatment of influenza and has been investigated for off-label use in treating other viral infections, including COVID-19. It inhibits the RNA-dependent RNA polymerase of RNA viruses. It is approved for influenza treatment in Japan but not widely approved elsewhere.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in healthy adult subjects after oral administration.</p><h4>References</h4><ol><li><p>Devireddy, VSR, et al., &amp; Misra, A (2024). Comparative Preclinical Pharmacokinetics and Disposition of Favipiravir Following Pulmonary and Oral Administration as Potential Adjunct Therapy Against Airborne RNA Viruses. <i>Pharmaceutical research</i> 41(11) 2189–2198. DOI:<a href=&quot;https://doi.org/10.1007/s11095-024-03782-3&quot;>10.1007/s11095-024-03782-3</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/39419926/&quot;>https://pubmed.ncbi.nlm.nih.gov/39419926</a></p></li><li><p>Siripongboonsitti, T, et al., &amp; Mahanonda, N (2023). Pharmacokinetic Comparison of Favipiravir Oral Solution and Tablet Formulations in Healthy Thai Volunteers. <i>Clinical pharmacology in drug development</i> 12(1) 14–20. DOI:<a href=&quot;https://doi.org/10.1002/cpdd.1149&quot;>10.1002/cpdd.1149</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/35877195/&quot;>https://pubmed.ncbi.nlm.nih.gov/35877195</a></p></li><li><p>Hayden, FG, et al., &amp; Kang, LL (2024). Oral Favipiravir Exposure and Pharmacodynamic Effects in Adult Outpatients With Acute Influenza. <i>The Journal of infectious diseases</i> 230(2) e395–e404. DOI:<a href=&quot;https://doi.org/10.1093/infdis/jiad409&quot;>10.1093/infdis/jiad409</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/37739792/&quot;>https://pubmed.ncbi.nlm.nih.gov/37739792</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end J05AX27;
